Skip to content
Buy This GLP
← Research
Evidence

GLP-1 Persistence Definitions: How the Refill Gap Changes the Estimate

Across seven studies, persistence often fell below 60% by 12 to 24 months. The figures differ with how many days without a refill count as stopping.

Editorial profile: Neil SandersBuy This GLP Editorial Team6 min read
The same patient, three definitions of “stopped”a short allowed gapcounts a pause as a stopa longer allowed gapcounts a stop as a pauseDiscontinuation hit 64.1% at two years in one large cohort.Seven studies. Only two asked anybody why.

Two studies can estimate how long people stay on a GLP-1 and arrive at different answers for similar populations. One reason is the number of days without a refill each study allows before it counts someone as having stopped.

How stopping gets counted

Persistence in this literature is measured from pharmacy refills. [1] You are persistent until a gap opens between refills that is longer than some allowed threshold, and that threshold is a choice the analyst makes.

Allow a short gap and a person who was late by a few weeks is recorded as having stopped. Allow a long one and a person who genuinely quit stays counted as continuing for months. The review found estimates varying by exactly this, and by the analytic approach used around it.

What the numbers came to

In one study, estimated persistence at 12 months was 32.8% versus 51.0% when the researchers allowed a 30-day versus a 90-day refill gap [1]. A separate cohort reported 64.1% discontinuation at two years [1].

Persistence varied with age, income, gastrointestinal side effects, how much weight came off, body mass index measures, which agent, which formulation and the dosing schedule. Some of those are clinical. Income is not.

The part nobody studied

Only two of the seven studies reported patient-level reasons for stopping, most commonly adverse effects. None described any structured behavioral or supportive strategy.

A gap in dispensing records cannot show why someone stopped or what happened when they resumed. The research on restarting after a gap explains why the time off medication matters when discussing a restart with a prescriber.

What a buyer takes from it

When you meet a persistence figure, ask what gap it allowed. A site quoting “two thirds stop within a year” and a study reporting 64.1% at two years may be describing the same behavior with different rulers.

The review included adults with both obesity and type 2 diabetes. A separate study of people offered self-pay liraglutide examined why patients declined to start treatment. It measured a different decision from stopping after a prescription had been filled.

Use the six-month cost tool to compare quotes for the same treatment period. Check the cancellation terms if you plan to pay before all the medication ships.

Frequently asked

How many people stay on these drugs?
Persistence often fell below 60% by 12 to 24 months across seven studies, and discontinuation reached 64.1% at two years in one large cohort.
Why do persistence figures disagree?
Because they are measured from refill gaps, and how long a gap counts as stopping is a choice the analyst makes. Different thresholds produce different percentages from the same behavior.
Do people who stop come back?
Interruption followed by restarting was common, which is why the definition matters. A strict rule counts returners as quitters; a loose one counts quitters as continuing.
Do we know why people stop?
Two of the seven studies reported patient-level reasons for stopping. Adverse effects were the most common reason reported. None described a structured support strategy.

Sources

  1. [1] Wang T, et al. (2026). Persistence in GLP-1-Based Therapy Among Adults with Obesity and Type 2 Diabetes: A Narrative Review of Definitions, Real-World Outcomes, and Determinants Current Diabetes Reports. PMID 42603234

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence